BR0309783A - Inibidores de quinases de pontos de controlo (wee1 e chk1) - Google Patents

Inibidores de quinases de pontos de controlo (wee1 e chk1)

Info

Publication number
BR0309783A
BR0309783A BR0309783-8A BR0309783A BR0309783A BR 0309783 A BR0309783 A BR 0309783A BR 0309783 A BR0309783 A BR 0309783A BR 0309783 A BR0309783 A BR 0309783A
Authority
BR
Brazil
Prior art keywords
wee1
chk1
control point
kinase inhibitors
point kinase
Prior art date
Application number
BR0309783-8A
Other languages
English (en)
Inventor
Richard John Booth
William Alexander Denny
Ellen Myra Dobrusin
Alan John Kraker
Lorna Helen Mitchell
Jeffrey Bruce Smaill
Andrew Mark Thompson
Ho Huat Lee
Florence Oliver Josep Mccarthy
Brian Desmond Palmer
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0309783A publication Critical patent/BR0309783A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"INIBIDORES DE QUINASES DE PONTOS DE CONTROLO (WEE1 E CHK1)". Esta invenção relaciona-se com derivados de pirrolocarbazole de acordo com a fórmula (I) em que R^ 1^, R^ 2^, R^ 7^, R^ 8^, R^ 9^, X e Y são como definidos na especificação em que os referidos derivados inibem especificamente uma ou ambas as quinases de <39>ponto de controlo<39>0 Wee1 e Chk1.
BR0309783-8A 2002-04-26 2003-04-15 Inibidores de quinases de pontos de controlo (wee1 e chk1) BR0309783A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37580602P 2002-04-26 2002-04-26
PCT/IB2003/001417 WO2003091255A1 (en) 2002-04-26 2003-04-15 Inhibitors of checkpoint kinases (wee1 and chk1)

Publications (1)

Publication Number Publication Date
BR0309783A true BR0309783A (pt) 2005-03-22

Family

ID=29270703

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309783-8A BR0309783A (pt) 2002-04-26 2003-04-15 Inibidores de quinases de pontos de controlo (wee1 e chk1)

Country Status (7)

Country Link
EP (1) EP1501831A1 (pt)
JP (1) JP2006504632A (pt)
AU (1) AU2003224341A1 (pt)
BR (1) BR0309783A (pt)
CA (1) CA2483496A1 (pt)
MX (1) MXPA04010617A (pt)
WO (1) WO2003091255A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1869020E (pt) 2005-03-29 2010-12-23 Icos Corp Derivados de heteroaril-ureia úteis para a inibição de chk1
AR060635A1 (es) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
AU2008315048A1 (en) 2007-10-23 2009-04-30 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
CA2750716A1 (en) 2009-02-25 2010-09-02 Msd K.K. Pyrimidopyrimidoindazole derivative
SI2477628T1 (sl) 2009-09-15 2014-11-28 Merck Sharp & Dohme Corp. Priprava oblik kristalinskega hemihidrata dihidropirazolopirimidinona
CN103764604B (zh) * 2011-01-28 2017-02-08 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
JP6569908B2 (ja) * 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2019165204A1 (en) 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
GB2239013B (en) * 1989-11-01 1993-06-02 Toyama Chemical Co Ltd Novel isoindole derivatives and salts thereof,processes for producing the same and antitumor agent comprising the same
ES2123873T3 (es) * 1994-08-04 1999-01-16 Hoffmann La Roche Pirrolocarbazol.
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof

Also Published As

Publication number Publication date
CA2483496A1 (en) 2003-11-06
EP1501831A1 (en) 2005-02-02
JP2006504632A (ja) 2006-02-09
MXPA04010617A (es) 2004-12-13
AU2003224341A1 (en) 2003-11-10
WO2003091255A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
BR0309783A (pt) Inibidores de quinases de pontos de controlo (wee1 e chk1)
BRPI0506662A (pt) composto
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
BRPI0616630B8 (pt) compostos de pirazol substituídos
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
ATE543521T1 (de) Calciumphosphat-zement
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
DE602005023333D1 (de) Kinaseinhibitoren
BRPI0518758A2 (pt) compostos de acetamida como fungicidas
BR0308211A (pt) Cumarinas úteis como biomarcadores
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0919873A2 (pt) composto de pirazol[1,5-a]pirimidina substituídos como inibidores da quinase trk
BR0307960A (pt) N-aminoacetil-pirrolidina-2-carbonitrilas e seu uso como inibidores de ddp-iv
HN2003000227A (es) Inhibidores de quinasas
NO20070334L (no) 4,6-disubstituerte pyrimidiner og deres anvendelse som proteinkinaseinhibitorer
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
BRPI0413973A (pt) compostos
TW200801008A (en) Protein kinase inhibitors
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
BR112013000868A2 (pt) derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
BR0213129A (pt) Pró-drogas de compostos policìclicos substituìdos, úteis para inibição seletiva da cascata da coagulação
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
BR0013081A (pt) Pirimidino-2,4,6-trionas inibidoras de metaloproteinases
BRPI0411897A (pt) pirroldihidroisoquinolinas como inibidores de pde10

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2051 DE 27/04/2010.